Zheng Quan Zhi Xing·2025-07-25 16:25Core Viewpoint - The report outlines the verification opinions of China International Capital Corporation regarding the lifting of restrictions on the circulation of part of the restricted shares of Shanghai Mengke Pharmaceutical Co., Ltd. The restricted shares will be available for trading on August 5, 2025, involving a total of 159,444,366 shares, which accounts for 24.32% of the company's total share capital [1][3][8]. Group 1: Restricted Shares Details - The total number of shares after the initial public offering (IPO) is 655,210,084, with 118,687,659 shares being unrestricted and 536,522,425 shares being restricted [2]. - The restricted shares involved in this circulation are from five shareholders, with a lock-up period of 36 months from the date of the company's stock listing [3]. - The total number of restricted shares to be listed for circulation is 159,444,366, which will be available for trading on August 5, 2025 [4][6]. Group 2: Share Capital Changes - Following the implementation of the 2023 restricted stock incentive plan, the company's total share capital increased from 655,210,084 shares to 655,605,491 shares [3]. - The increase in share capital is attributed to the vesting of restricted stocks under the incentive plan [3]. Group 3: Shareholder Commitments - Shareholders have made commitments regarding the locked shares, including not transferring or proposing to repurchase the shares during the lock-up period of 36 months [5][6]. - After the lock-up period, shareholders plan to reduce their holdings in compliance with relevant laws and regulations, ensuring that the selling price will not be lower than the IPO price adjusted for any corporate actions [5][6]. Group 4: Verification Opinions - The sponsor institution, China International Capital Corporation, has verified that the application for the lifting of restrictions on the shares complies with relevant laws and regulations, and the shareholders have adhered to their commitments made during the IPO [7][8].